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Abstract Drug-induced hyperkalemia is not uncommon
and may be life-threatening when presenting acutely in the
emergency department. We present a case of severe hyper-
kalemia precipitated acutely by etoricoxib in a patient who
was on telmisartan and a low sodium (potassium chloride-
rich) diet. A 75-year-old male with a past medical history of
well-controlled diabetes and hypertension was prescribed
etoricoxib (90 mg daily) for 3 days for musculoskeletal
backache. He had been taking his routine medications
including telmisartan and a potassium-rich salt substitute
for many years, without any recent change in dosage or
quantity. There was evidence of microalbuminurea;
however, the renal functions and electrolytes prior to
starting etoricoxib were normal. He presented to the
emergency department with signs and symptoms of life-
threatening hyperkalemia (serum potassium 7.7 mEq/dl),
accelerated hypertension, congestive heart failure, pulmo-
nary edema and acute renal failure. Acute medical
management and withholding all drugs that could cause
hyperkalemia improved his serum potassium levels over 24
h and renal parameters within 5 days. All the other drugs
except etoricoxib were restarted under observation over
8 weeks with no recurrence of the acute episode. Non-
steroidal analgesics and other COX-2 inhibitors (rofecoxib
and celecoxib) have been known to precipitate renal failure
and hyperkalemia specially in patients at risk for the same;
although not unexpected, this may be the first reported case
of life-threatening hyperkalemia precipitated by etoricoxib





Medications have been cited as a primary or contributing
cause of hyperkalemia in 35% to 75% of hospitalized patients
[1]. Nonsteroidal anti-inflammatory drugs (NSAIDs) may
be associated with more than 10% of these cases [2].
COX-2 inhibitors appear to have similar effects to
NSAIDS via the inhibition of renal prostaglandin synthesis
[3]. The susceptibility to drug-induced hyperkalemia is
higher in patients with impaired renal function, diabetes
mellitus and states of impaired potassium homeostasis such
as hypoaldosteronism [4].
Case report
A 75-year-old male patient presented to the emergency
department in acute respiratory distress. The patient had a
history of diabetes, hypertension and hyperthyroidism
lasting for several years. His blood pressure, blood sugar
(including Hb1Ac) and thyroid status were well controlled
with medicines (Table 1). For the last 5 years, he had been
on a ‘low salt’ diet under medical advice. The ‘light salt’
diet is primarily composed of potassium chloride salt
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DOI 10.1007/s12245-010-0208-6(approximate consumption 3.5 g/day). There were no recent
changes in his diet or medications. He had not been on any
herbal medications, potassium supplements, potassium-sparing
diuretics or over-the-counter analgesics. He had documented
evidence of diabetic neuropathy and microalbuminurea (nor-
mal creatinine clearance by the Cockroft-Gault formula), which
had not been deteriorating up to his last routine examination 1
month prior to admission (Table 2). An electrocardiogram
done 15 days prior to this emergency admission did not show
any changes suggestive of hyperkalemia such as tall t waves,
increased PR interval or broad QRS complex.
The patient was treated 5 days prior to admission for low
backache of musculoskeletal origin by his regular physician
who prescribed etoricoxib 90 mg/day for 3 days. He had
taken the last dose 48 h prior to presenting to us. He had
complaints of nausea, weakness, lassitude, swelling of the
legs and dyspnea for the last 72 h with gradually increasing
respiratory distress.
On presentation our patient was afebrile, with a pulse
rate of 60/min, blood pressure 180/90 mmHg, respiratory
rate 30 per minute and oxygen saturation of 82% on room
air. Examination showed a moist tongue, bilateral pitting
pedal edema, raised jugular venous pressure and crepita-
tions at the lung bases bilaterally.
Oxygen inhalation and 40 mg intravenous furosemide
were given, and the patient was shifted to the intensive care
unit promptly as his restlessness increased. The electrocar-
diogram done here showed a heart rate of 38/min with a
near sine wave pattern that was broad QRS complex, with
absent p waves and tall tented T waves in lead II (Fig. 1).
Aggressive medical management of hyperkalemia (revealed
in the blood gas electrolyte study) with 10 ml of 10% calcium
gluconate, hourly nebulization with salbutamol and glucose
with insulin infusion administered intravenously (25% dex-
trose, 100 ml, with 10 units of regular insulin) reverted the
electrocardiogram changes (Fig. 2) and decreased the serum
potassium level after 8 h to 6.5 meq/dl. Telmisartan,
torsemide, hydrochlorthiazide and light salt were discontin-
ued. Parenteral furesemide (40 mg twice a day), tramadol (an
opioid analgesic) for pain relief and the addition of salt to the
diet were instituted. Respiratory status improved, and pedal
edema resolved within 24 h. Biochemical parameters (Table 2)
revealed life-threatening hyperkalemia, deranged renal func-
tion and hyponatremia. Complete blood count with a
differential, serum-free T3, T4, TSH and lipid profile was
withinnormallimits.Urinalysisonadmissionshoweda pHof
5.0, specific gravity 1.005, 2+ protein, 2+ glucose, negative
ketones and no microbiological growth on culture. Urine
sedimentshowedfewepithelialcellsandgranularcasts.Urine
sodium concentration was 96 mEq/l. The chest radiograph
showed cardiomegaly and cardiogenic pulmonary edema.
Echocardiogram showed a left ventricular hypertrophy with
a good left ventricular systolic function. Renal ultrasonogram
showed no evidence of hydronephrosis, significant prostato-
megaly or other masses. On fundus examination, posterior
segment details were unremarkable.
There was a return of serum potassium to normal levels
within 24 h. Serum sodium gradually improved over 6 days
to 130 meq/dl. Serum urea decreased to pre-admission
values by day 5 when he was discharged. The case was
discussed with his primary physician, and with the consent
of the patient, telmisartan and a low salt supplement were
carefully restarted one at a time. On follow-up at 2 months,
he had restarted all his previous medications including
telmisartan, and his electrolyte and renal parameters were at
his usual baseline levels.
Discussion
The NSAID etoricoxib is a selective inhibitor of cyclo-
oxygenase 2 (COX-2) approved for treatment of patients
with chronic arthropathies and musculoskeletal and dental
pain [5]. Like parecoxib, celecoxib and other selective
COX-2 inhibitors, it has demonstrated a significant reduc-
tion in gastrointestinal toxicity, although its renal adverse
effects appear to be similar to those of other NSAIDs. The
Table 1 Patient medications
Medications Dose Route Frequency
Nifedipine 20 mg Orally Twice a day
Telmisartan/
hydrochlorthiazide
40 mg Oral Once a day
Torsemide 10 mg Oral Once a day
Atorvastatin 10 mg Oral Once a day
Ecospirin 75 mg Oral Once a day
Levothyroxine 50 μg Oral Once a day
Insulin mixtard (30:70) 34U/24 U Subcutaneous
-3M -1M D1 D2 D3 D4 D5
Serum urea (12–25 mg/dl) 38 42 62 78 63 52 45
Serum creatinine(0.5–1.2 mg/dl) 1.3 1.2 1.8 2.3 1.9 1.5 1.2
Serum sodium (136–145 meq/dl) - 132 103 109 117 123 130
Serum Potassium (3.5–5.3 meq/dl) - 3.8 7.7 4.7 3.6 3.8 3.5
Table 2 Biochemical
parameters
-3 M: 3 months prior to admis-
sion, -1 M: 1 month prior to
admission, D: day
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inhibitors like myocardial infarction, hypertension, fluid
retention and congestive heart failure, among others, have
led to a revoking of Merck’s Vioxx (rofecoxib) and the
unavailabilityof Arcoxia (etoricoxib) inthe USA [6, 7]. They
are widely prescribed in Europe, South America and Asia for
musculoskeletal pain. They are preferred over other NSAIDS
mainly due to the favorable gastrointestinal profile and
convenience of single-day dosing. It is available as an off-
the-counter drug in India.
Specific COX-2 inhibition may induce renal ischemia,
electrolyte imbalance and increased blood pressure, ulti-
mately leading to fluid and sodium retention and decreased
GFR [8]. In elderly patients on a sodium-depleted diet, a
drop in GFR may be significant after a single dose of COX-
2 inhibitor [9].
In our case, acute renal insult and inhibition of prostaglan-
din I2 (which increases potassium secretion) as a result of
COX-2 inhibition is the proposed mechanism precipitating
hyperkalemia in our patient who was already on ‘low salt’
supplements rich in potassium and telmisartan, which causes
hyperkalemia by inducing a state of hypoaldosteronism [10].
The time course of events, absence of other precipitating
causes of renal dysfunction or hyperkalemia, rapid improve-
ment on stopping the drug with no recurrence on reintro-
duction of the other medications and diet make etoricoxib
the most probable cause (Naranjo score 7).
Fig. 1 The initial 12-lead ECG (25 mm/s, 5 mm/mV) obtained on presentation to the emergency department demonstrates a sinus bradycardia
with prolonged atrial conduction (flattened P waves) and an intraventricular conduction delay (QRS, 154 ms)
Fig. 2 Lead II of the ECG done after an hour of initiation of medical
management showing improvement of heart rate and reappearance of
the p waves
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inhibition may cause edema, hypertension and acute renal
failure in a minority of patients. It may exacerbate pre-
existing hypertension. The number and spectrum of these
side effects have been greater with rofecoxib than with the
other COX-2 inhibitors, presumably due to the non-class
effects of these drugs as their chemical structures are
different [11].
In 14 cases of COX-2 inhibitor (celecoxib and rofe-
coxib) associated acute renal failure reported by Perazella et
al. [12], all the patients had several risk factors for NSAID-
induced nephrotoxicity, including renal compromise and
multiple medications. Acute renal failure, disturbances in
volume status (heart failure, edema), acidosis and hypona-
tremia were common. Twelve patients developed hyper-
kalemia (>5.1 meq/dl) and four required hemodialysis.
Similar to our case, treatment before the development of
clinically recognized renal failure ranged from 4 days to
3 weeks, and resolution of the renal dysfunction took
2 days to 3 weeks after discontinuation of drugs and
supportive therapy.
More specifically for etoricoxib, recent data from the
large MEDAL (Multinational Etoricoxib vs. Diclofenac
Arthritis Long Term) program, which enrolled 34,000
arthritis patients over 18 months, show clinically important
increases in renal function endpoints. There was no
significant increase in the incidence of hyperkalemia [13].
Unlike in healthy people, patients with edematous con-
ditions requiringdietarysodiumrestrictionand diuretics,such
as those with chronic renal insufficiency, congestive heart
failure, chronic liver disease and hypertension, should be
treated cautiously with COX-2 inhibitors. Electrolytes and
renal function should be checked 1–2 weeks after initiation of
COX-2 inhibitors in these patients to screen for hyperkalemia
and renal insufficiency [14, 15].
An Internet search (Google scholar and MedLine) with
the words ‘hyperkalemia’/‘acute renal failure’/‘COX-2
inhibitors’/‘adverse drug reactions’ and ‘etoricoxib’ did
not yield any results, making our case possibly the first
such in the literature.
Conclusion
Even a short duration of treatment with the new COX-2
inhibitor etoricoxib may have the potential to precipitate
renal failure and life-threatening hyperkalemia when ad-
ministered to selected patients. The importance of consid-
ering a patient’s existing diet, medications and systemic
status before writing a new prescription that may interfere
with the potassium physiology cannot be overstressed.
Consent
Written informed consent was obtained from the patient (or
the patient’s relatives) for publication of this case report.
Competing interests Theauthorsdeclare thattheyhavenocompeting
interests.
Authors contributions S.T. was involved in clinical management of
the patient and in the manuscript preparation.
S.D. was involved in manuscript reviewing and editing apart from
clinical patient care.
Reference
1. Perazella MA (2000) Drug induced hyperkalemia: old culprits and
new offenders. Am J Med 109:307–314
2. Acker CG, Johnson JP, Palevsky PM, Greenberg A (1998)
Hyperkalemia in hospitalized patients. Arch Int Med 158:917–924
3. HarrisRC(2002) Cyclooxygenase-2inhibitionandrenalphysiology.
Am J Cardiol 89(Suppl):10D–17D
4. Lam Q, Schneider HG (2005) Hyperkalaemia with
cyclooxygenase-2 inhibition and hypoaldosteronism. Intern
Med J 35(9):572–573
5. Takemoto JK, Reynolds JK, Remsberg CM, Takemoto JK, Reynolds
JK, Remsberg CM, Vega-Villa KR, Davies NM (2008) Clinical
pharmacokinetic and pharmacodynamic profile of etoricoxib. Clin
Pharmacokinet 47:703–720
6. Krumholz HM, Ross SJ, Presler AH, Egilman DS (2007) What
have we learnt from Vioxx? BMJ 334:120–123
7. Young D (2007) Few options available for arthritis pain refief.
FDA declines to approve Merc’s Arcoxia. Am J Health Syst
Pharm 64:1020–1022
8. Sharma JN, Jawad NM (2005) Adverse effects of COX-2
inhibitors. Scientific World Journal 5:629–645
9. Akinbamowo AO, Salzberg DJ, Weir MR (2008) Renal con-
sequences of prostaglandin inhibition in heart failure. Heart Fail
Clin 4(4):505–510
10. Omalhassan A, Yahaya H, Sarriff A (2009) Incidence of risk
factor for developing hyperkalemia when using ACE inhibitors in
cardiovascular diseases. Pharm World Sci 31:387–393
11. Zhang J, Ding EL, Song Y (2006) Adverse effects of cyclo-
oxygenase 2 inhibitors on renal and arrhythmia events: meta-
analysis of randomised trials. JAMA 296:1619–1632
12. Perazella MA, Tray K (2001) Selective cyclooxygenase-2 inhib-
itors: a pattern of nephrotoxicity similar to traditional nonsteroidal
anti-inflammatory drugs. Am J Med 111:64–67
13. Cannon CP, Curtis SP, FitzGerald GA et al (2006) Cardiovascular
outcomes with etoricoxib and diclofenac in patients with
osteoarthritis and rheumatoid arthritis in the Multinational
Etoricoxib and Diclofenac Arthritis Long-term (MEDAL)
programme: a randomised comparison. Lancet 368:1771–1781
14. Braden G, O'shea MH, Mulhern JG, Germain MJ (2004) Acute
renal failure and hyperkalaemia associated with cyclooxygenase-2
inhibitors. Nephrol Dial Transplant 19:1149–1153
15. Harris RC, Breyer MD (2006) Update on cycloxygenase-2
inhibitors. Clin J Am Soc Nephrol 1:236–245
446 Int J Emerg Med (2010) 3:443–446